Final assembly of autoinjectors / on-body injectors (insert syringe, seat springs, snap closures)
Drug-delivery device assembly combines a filled glass syringe or cartridge with plastic housings, drive springs, plunger rods/backstops, needle shields, and caps into a functioning autoinjector or on-body injector. The robot performs a multi-step sequence: insert the fragile primary container into the device chassis, press-fit retention components, seat springs, and engage snap-fit closures and caps, all to sub-millimeter alignment. Components are small, mixed rigid-plastic and glass, of low tolerance to misalignment, and the finished device must reliably deliver dose. It is hard because each engagement must be FELT to confirm — over-force cracks the glass syringe or deforms plastic, under-force leaves an unseated component that fails function. AbbVie's pending acquisition of West's Tempe on-body-injector lines and its existing autoinjector packaging at Lake County make this an explicit, expanding capability. We identified this through our own research; we have not confirmed the specifics with the customer directly. This page is our researched read — a starting point for that conversation.
What the task is
RESEARCHED · our reconstructionDrug-delivery device assembly combines a filled glass syringe or cartridge with plastic housings, drive springs, plunger rods/backstops, needle shields, and caps into a functioning autoinjector or on-body injector. The robot performs a multi-step sequence: insert the fragile primary container into the device chassis, press-fit retention components, seat springs, and engage snap-fit closures and caps, all to sub-millimeter alignment. Components are small, mixed rigid-plastic and glass, of low tolerance to misalignment, and the finished device must reliably deliver dose. It is hard because each engagement must be FELT to confirm — over-force cracks the glass syringe or deforms plastic, under-force leaves an unseated component that fails function. AbbVie's pending acquisition of West's Tempe on-body-injector lines and its existing autoinjector packaging at Lake County make this an explicit, expanding capability.
Is this the actual task and sequence? What are the real tolerances, cycle rate, and reject criteria, and which steps are today's manual bottleneck? Answering these is what turns this from a researched signal into a validated use case.